Medipee | Updates

By Thomas Prokopp

Funding from Horizon 2020 and Medipee in the final stretch


Funding from “Horizon 2020” and Final Call for Medipee


Dear Companists,

Our campaign on Companisto is coming to a close, which is why we would like to take this opportunity to thank all who have supported Medipee.

We have some good news for you: After already having received the EU “Seal of Excellence” (see Update 5), we were able to convince the European Commission with another application and are now receiving financial support in sum of € 50,000 through the “Horizon 2020” program.


What is the “Horizon 2020” program?

“Horizon 2020” is a program to support innovative SME with great potential for growth throughout Europe. This funding helps us advance technical developments, to hone in on use cases, and to carry out preparations for the field tests in summer.


Field tests

We are currently conducting several conversations with representatives of health insurance companies, nursing homes, and the medical profession to find suitable partners for our field tests. The responses have demonstrated not only new fields of application but also great interest in collaborations. Many of our discussion partners have recognized the practical, time-related, and financial advantages that our solution offers them. Furthermore, their statements confirm the growing trend toward digitalization in the health care system.

Thank you to the many Companists who responded to our call for applications for our field tests. We were very pleased with your engagement and motivation. We will notify you once we take the next step in planning the tests and look forward to working with you!


The future

The coming months will be devoted to the further development and testing of our system before we start preparing for market entry at the end of the year. The positive feedback, the media response, and the increased activities on the market show us that we are on the right track.

Therefore we are eagerly looking forward to the future.


With kind regards,
Your Medipee team


Only registered Companists can comment. Please log in to leave a comment.


Investments in startups and growth companies offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, investments in startups or growth companies are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by diversifying the amount they invest in startups and growth companies and not investing the entire amount in one startup or growth company. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the investors on Companisto are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the investors (Companists) – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, investments in startups and growth companies are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

€ 174,200




12.28 %

Share Offered

Please note
The acquisition of this asset involves considerable risks and can lead to the complete loss of the assets used. The expected yield is not guaranteed and may turn out to be lower.
Contact Us
If you have any questions about investing on Companisto, please contact our service team:

Toll-free phone number for investors

0800 - 100 267 0 (DE)
0800 - 100 267(AT / CH)

We are available Monday through Friday between 9 a.m. – 7 p.m.

For companies
Apply for financing Investment Model FAQ for Companies
Investor Support
Please register in order to see the complete profile of Medipee.
Already registered?    Log in